{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:17:27Z","timestamp":1791346647332,"version":"4.3.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0046"],"award-info":[{"award-number":["2024NSFSC0046"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZYGD24003"],"award-info":[{"award-number":["ZYGD24003"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC32530059"],"award-info":[{"award-number":["NSFC32530059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.apsb.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:39:07Z","timestamp":1777073947000},"page":"5452-5470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted nanoparticles with triggered lysosomal escape enable anti-angiogenic immunotherapy for peritoneal metastatic colorectal cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Meng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-4953","authenticated-orcid":false,"given":"Yicong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danrong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-3027","authenticated-orcid":false,"given":"Zhiyong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.04.016_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.canep.2014.04.004","article-title":"Patterns of metachronous metastases after curative treatment of colorectal cancer","volume":"38","author":"van Gestel","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.apsb.2026.04.016_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br J Surg"},{"key":"10.1016\/j.apsb.2026.04.016_bib3","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3748\/wjg.v18.i39.5489","article-title":"Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options","volume":"18","author":"Klaver","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2026.04.016_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10585-016-9791-0","article-title":"Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options","volume":"33","author":"Sluiter","year":"2016","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.apsb.2026.04.016_bib5","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.3748\/wjg.v22.i34.7692","article-title":"Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum","volume":"22","author":"Lemoine","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2026.04.016_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/2159-8290.CD-12-0345","article-title":"Cancer cell metabolism: one hallmark, many faces","volume":"2","author":"Cantor","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.04.016_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.04.016_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/DCR.0000000000002315","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review","volume":"65","author":"Parikh","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.apsb.2026.04.016_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.04.016_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.04.016_bib11","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1002\/jcp.27414","article-title":"Challenges facing antiangiogenesis therapy: the significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies","volume":"234","author":"Mahdi","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2026.04.016_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2015.02.005","article-title":"Intertwined regulation of angiogenesis and immunity by myeloid cells","volume":"36","author":"Rivera","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2026.04.016_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.04.016_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/15548627.2024.2421699","article-title":"Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1\/HIF2\u03b1","volume":"21","author":"Li","year":"2025","journal-title":"Autophagy"},{"key":"10.1016\/j.apsb.2026.04.016_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.04.016_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.04.016_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.04.016_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.04.016_bib19","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1158\/1078-0432.CCR-07-0472","article-title":"A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment","volume":"13","author":"Strauss","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.04.016_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.04.016_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s43018-022-00353-6","article-title":"Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs","volume":"3","author":"Hongu","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2026.04.016_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.04.016_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10585-020-10024-4","article-title":"Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer","volume":"37","author":"Kastelein","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.apsb.2026.04.016_bib24","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.04.016_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.04.016_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2026.04.016_bib27","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.apsb.2022.11.013","article-title":"An mRNA vaccine elicits STING-dependent antitumor immune responses","volume":"13","author":"Chen","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.04.016_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099988","article-title":"DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2\u20323\u2032-cGAMP, induces M2 macrophage repolarization","volume":"9","author":"Downey","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.04.016_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cell.2013.07.023","article-title":"Structure\u2013function analysis of STING activation by c[G(2\u2032,5\u2032)pA(3\u2032,5\u2032)p] and targeting by antiviral DMXAA","volume":"154","author":"Gao","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.04.016_bib30","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","article-title":"An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.04.016_bib31","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review","volume":"7","author":"van Stein","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2026.04.016_bib32","article-title":"A DNA\/DMXAA\/metal-organic framework activator of innate immunity for boosting anticancer immunity","volume":"35","author":"Chen","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.04.016_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molmed.2015.01.001","article-title":"Cancer nanomedicine: from targeted delivery to combination therapy","volume":"21","author":"Xu","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2026.04.016_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2022.06.044","article-title":"An update on dual targeting strategy for cancer treatment","volume":"349","author":"Taghipour","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.04.016_bib35","article-title":"Cu2+-coordinated NLG919: a drug delivery nanoplatform to activate antitumor immunity via inducing immunogenic cell death and inhibiting indoleamine 2,3-dioxygenase-1","volume":"4","author":"Zhao","year":"2025","journal-title":"MedComm Biomater Appl"},{"key":"10.1016\/j.apsb.2026.04.016_bib36","article-title":"Drug delivery systems for colorectal cancer chemotherapy","volume":"35","author":"Chen","year":"2024","journal-title":"Chinese Chem Lett"},{"key":"10.1016\/j.apsb.2026.04.016_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.746646","article-title":"Recent advancements in serum albumin-based nanovehicles toward potential cancer diagnosis and therapy","volume":"9","author":"Shen","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.apsb.2026.04.016_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.apsb.2017.11.005","article-title":"Biomacromolecules as carriers in drug delivery and tissue engineering","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.04.016_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/bjs.4516","article-title":"Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"91","author":"Verwaal","year":"2004","journal-title":"Br J Surg"},{"key":"10.1016\/j.apsb.2026.04.016_bib40","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1016\/j.apsb.2025.09.031","article-title":"Hemoglobin nanocatalyst with tunable autoxidation activity for tumor apoptosis-ferroptosis combination therapy","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.04.016_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.apsb.2026.04.016_bib42","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1016\/j.apsb.2025.08.003","article-title":"Arsenic trioxide-based nanoparticles for enhanced chemotherapy by activating pyroptosis","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.04.016_bib43","doi-asserted-by":"crossref","first-page":"7417","DOI":"10.7150\/thno.33470","article-title":"Targeting and microenvironment-improving of phenylboronic acid-decorated soy protein nanoparticles with different sizes to tumor","volume":"9","author":"Qian","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.04.016_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113622","article-title":"ATP-responsive tumor targeted lipid nanoparticle for enhanced siRNA delivery and improved treatment efficacy in melanoma","volume":"382","author":"Xiong","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.04.016_bib45","doi-asserted-by":"crossref","first-page":"20927","DOI":"10.1021\/jacs.1c09741","article-title":"Phenylboronic acid modification augments the lysosome escape and antitumor efficacy of a cylindrical polymer brush-based prodrug","volume":"143","author":"Wang","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.04.016_bib46","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/acs.biomac.2c00482","article-title":"Phenylboronic acid-functionalized copolypeptides: facile synthesis and responsive dual anticancer drug release","volume":"23","author":"Zhang","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.apsb.2026.04.016_bib47","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.apsb.2023.12.001","article-title":"A pH\/ROS dual-responsive system for effective chemoimmunotherapy against melanoma via remodeling tumor immune microenvironment","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.04.016_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/cmi.2014.6","article-title":"Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60","volume":"11","author":"Yang","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2026.04.016_bib49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.04.016_bib50","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jconrel.2023.06.036","article-title":"Emerging role of interactions between tumor angiogenesis and cancer stem cells","volume":"360","author":"Lv","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.04.016_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2023.341360","article-title":"In-depth size and charge variants characterization of monoclonal antibody with native mass spectrometry","volume":"1265","author":"Dai","year":"2023","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.apsb.2026.04.016_bib52","article-title":"An \"AND\" logic-gated prodrug micelle locally stimulates antitumor immunity","volume":"36","author":"Chen","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.04.016_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202410536","article-title":"Eradication of large tumors by nanoscale drug self-assembly","volume":"36","author":"Su","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.04.016_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301826","article-title":"Novel natural carrier-free self-assembled nanoparticles for treatment of ulcerative colitis by balancing immune microenvironment and intestinal barrier","volume":"12","author":"Gao","year":"2023","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2026.04.016_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202314095","article-title":"Emerging co-assembled and sustained released natural medicinal nanoparticles for multitarget therapy of choroidal neovascularization","volume":"36","author":"Shen","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.04.016_bib56","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jconrel.2020.11.024","article-title":"Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy","volume":"330","author":"Lim","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.04.016_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biochi.2019.02.012","article-title":"Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles","volume":"160","author":"Ahmad","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.apsb.2026.04.016_bib58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.04.016_bib59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ijbiomac.2018.06.026","article-title":"Folic acid conjugated bovine serum albumin: an efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells","volume":"117","author":"Nosrati","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2026.04.016_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126114","article-title":"Developing targeted drug delivery carriers for breast cancer using glutathione-sensitive doxorubicin-coupled glycated bovine serum albumin nanoparticles","volume":"249","author":"Hsu","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2026.04.016_bib61","first-page":"669","article-title":"Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles","volume":"5","author":"Zhao","year":"2010","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2026.04.016_bib62","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12951-023-02146-0","article-title":"Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of melanoma","volume":"21","author":"Wang","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2026.04.016_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128691","article-title":"Self-assembly of maltose-albumin nanoparticles for efficient targeting delivery and therapy in liver cancer","volume":"258","author":"Wang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2026.04.016_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.04.016_bib65","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.7150\/thno.19365","article-title":"Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery","volume":"7","author":"An","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.04.016_bib66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijbiomac.2021.10.040","article-title":"Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: a critical review","volume":"193","author":"Solanki","year":"2021","journal-title":"Int J Biol Macromol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526002649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526002649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:58:19Z","timestamp":1786481899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526002649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2211383526002649"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.04.016","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted nanoparticles with triggered lysosomal escape enable anti-angiogenic immunotherapy for peritoneal metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}